Follow the SynAct Pharma AB stock price and the full management transaction log of the company, a publicly traded company based in Finland. Shares trade on the FI market, under the authority of FIN-FSA. Operating in the Health Care sector, SynAct Pharma AB has recorded 0 public disclosures. Market capitalisation: €974.4m. The full history is free.
Analysts rate SynAct Pharma AB Strong Buy (bullish), based on 2 analysts. Average price target: SEK 35.00.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
No declarations found
0 of 0 declarations
SynAct Pharma AB is a biopharmaceutical company focused on developing treatments for inflammatory and autoimmune diseases. It is listed on the XSTO exchange.